1961/09/01 by Christian Lauritzen, Semih Velibese, A. Baudouin +5 · 2 citations
Biochemistry, Genetics and Molecular Biology · Engineering · Materials Science · #Estrogen and related hormone effects #Graphite, nuclear technology, radiation studies #Nuclear and radioactivity studies #Nuclear reactor physics and engineering
paper · doi:10.1530/acta.0.0380073
openalex publication_date 1981/01/01 · openalex created_date 2016/06/24 · openalex updated_date 2026/06/11
ABSTRACT A description is given of experimental investigations and preliminary clinical experience with the long-acting oestriol compound polyoestriol phosphate – a water-soluble polymere of oestriol and phosphoric acid. The compound seems to exert all the physiologically important effects of oestriol. Even with high doses the hormone causes no proliferation of the endometrium and no withdrawal bleeding. It has no untoward effect on metabolism. It decreases slightly the cholesterol concentration (to the extent of ⅓–⅕ of the effect produced by long-acting oestradiol esters). The compound has a wide therapeutic range. No side-effects have been observed. Doses of 10 mg or more have a prolonged duration. Additional prolongation of the effect is largely dependent on dosage. To ensure an effect lasting for 4 weeks 40 mg polyoestriol phosphate (corresponding with 30 mg oestriol) is required – an amount which roughly corresponds with physiological quantitative data. The compound, which involves an interesting new principle of prolongation, was most effectively used in the treatment of menopausal symptoms and genital organic disorders. For these indications it can be recommended without reservation.